ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

CYTO Altamira Therapeutics Ltd

1,10
-0,08 (-6,78%)
Nach Börsenschluss
Zuletzt aktualisiert: 00:10:33
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Altamira Therapeutics Ltd CYTO NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
-0,08 -6,78% 1,10 00:10:33
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
1,17 1,0501 1,1792 1,10 1,18
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
20.6.202415:01GLOBEAltamira Therapeutics Highlights Newly Published Review..
28.5.202416:31GLOBEAltamira Therapeutics Provides Business Update
23.5.202414:47GLOBEAltamira Therapeutics Announces Dissemination of Positive..
16.5.202422:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01.5.202414:47GLOBEAltamira Therapeutics Announces Filing of Provisional Patent..
24.4.202414:47GLOBEAltamira Therapeutics Announces Publication of Positive..
10.4.202414:00GLOBEAltamira Therapeutics Provides Business Update, Reports Full..
04.4.202414:45GLOBEAltamira Therapeutics to Host Full Year 2023 Financial..
25.3.202413:47GLOBEAltamira Therapeutics Announces Collaboration with..
07.2.202414:47GLOBEAltamira Therapeutics’ Peptide-Based Delivery Platform Shown..
24.1.202414:47GLOBEAltamira Therapeutics Files Second Provisional Patent..
22.1.202423:02EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
22.1.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
19.1.202422:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19.1.202422:40EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19.1.202422:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08.1.202423:02EDGAR2Form F-3 - Registration statement by foreign private issuers
08.1.202414:47GLOBEAltamira Therapeutics to Present at 3rd Annual mRNA-Based..
29.12.202314:47GLOBEAltamira Therapeutics Regains Compliance with Nasdaq Minimum..
11.12.202314:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11.12.202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11.12.202314:00GLOBEAltamira Therapeutics Provides Investor and Business Update
08.12.202315:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05.12.202318:54GLOBEAltamira Therapeutics to Host Investor & Business Update..
29.11.202316:20GLOBEAltamira Therapeutics Regains Compliance with Nasdaq Minimum..
22.11.202322:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21.11.202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17.11.202315:04GLOBEAltamira Therapeutics Announces Partial Spin-Off of Bentrio®..
10.11.202314:47GLOBEAltamira Therapeutics Announces European Patent Office..
31.10.202321:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04.10.202315:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14.9.202314:47GLOBEAltamira Therapeutics Reports Additional Significant..
12.9.202313:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12.9.202313:30GLOBEAltamira Therapeutics Provides Business Update and First..
06.9.202314:47GLOBEAltamira Therapeutics to Host First Half 2023 Financial..
23.8.202314:47GLOBEAltamira Therapeutics to Present at H.C. Wainwright 25th..
21.8.202313:31EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
28.7.202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26.7.202315:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20.7.202314:47GLOBEAltamira Therapeutics and Pharma Nordic Collaborate for..
17.7.202314:47GLOBEAltamira Therapeutics Announces Publication of Positive..
11.7.202314:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07.7.202322:14EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
05.7.202314:47GLOBEAltamira Therapeutics Announces Collaboration with Heqet..
30.6.202312:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..